Literature DB >> 2432970

Fibrinolysis in pregnancy: a study of plasminogen activator inhibitors.

E K Kruithof, C Tran-Thang, A Gudinchet, J Hauert, G Nicoloso, C Genton, H Welti, F Bachmann.   

Abstract

During pregnancy the plasma concentration of two different inhibitors of plasminogen activators (PAIs) increases. The only one found in the plasma of nonpregnant women (PAI1) is immunologically related to a PAI of endothelial cells; its plasma activity, as deduced from the inhibition of single-chain tissue-type plasminogen activator (t-PA), increased from 3.4 +/- 2.3 U/mL (mean +/- 95% confidence limits) in the plasma of nonpregnant women to 29 +/- 7 U/mL at term, and its antigen level, measured by a radioimmunoassay, increased from 54 +/- 17 ng/mL to 144 +/- 25 ng/mL. In pregnancy plasma a second PAI (PAI 2) related to a PAI found in placenta extracts was observed. Its level, quantified with a radioimmunoassay, increased from below the detection limit (approximately 10 ng/mL) in normal plasma to 260 ng/mL at term. One hour after delivery, PAI 1 activities and antigen decreased sharply, but the PAI 2 antigen levels remained constant. Three days later, the PAI 1 antigen levels had fallen to normal levels, but the PAI 2 antigen levels were still at least eightfold above the nonpregnant values. During pregnancy, the t-PA and prourokinase (u-PA) antigen concentrations increased 50% and 200%, respectively, whereas the plasminogen and alpha 2-antiplasmin levels remained constant. Despite the large variations in the levels of PAs and PAIs, the overall fibrinolytic activity as measured in diluted plasma by a radioiodinated fibrin plate assay did not change significantly. Just after delivery, a great increase in the t-PA antigen levels was observed. Three to five days after delivery most parameters of the fibrinolytic system were normal again. Our results demonstrate that during pregnancy and in the puerperium profound alterations of the fibrinolytic system occur that are characterized by increases in PAs and their inhibitors, but these alterations do not affect the overall fibrinolytic activity.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2432970

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  38 in total

Review 1.  Importance of mast cells in the pathophysiology of asthma.

Authors:  Seong H Cho; Andrea J Anderson; Chad K Oh
Journal:  Clin Rev Allergy Immunol       Date:  2002-04       Impact factor: 8.667

2.  Expression of tissue type and urokinase type plasminogen activators as well as plasminogen activator inhibitor type-1 and type-2 in human and rhesus monkey placenta.

Authors:  Z Y Hu; Y X Liu; K Liu; S Byrne; T Ny; Q Feng; C D Ockleford
Journal:  J Anat       Date:  1999-02       Impact factor: 2.610

3.  Gastrin activates paracrine networks leading to induction of PAI-2 via MAZ and ASC-1.

Authors:  Simon Almeida-Vega; Krista Catlow; Susan Kenny; Rod Dimaline; Andrea Varro
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-12-12       Impact factor: 4.052

4.  The cost-benefit ratio of screening pregnant women for thrombophilia.

Authors:  Gian Luca Salvagno; Giuseppe Lippi; Massimo Franchini; Giovanni Targher; Martina Montagnana; Massimo Franchi; Gian Cesare Guidi
Journal:  Blood Transfus       Date:  2007-11       Impact factor: 3.443

5.  The plasminogen activator inhibitor-2 gene is not required for normal murine development or survival.

Authors:  K M Dougherty; J M Pearson; A Y Yang; R J Westrick; M S Baker; D Ginsburg
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-19       Impact factor: 11.205

6.  An anticoagulant dermatan sulfate proteoglycan circulates in the pregnant woman and her fetus.

Authors:  M Andrew; L Mitchell; L Berry; B Paes; M Delorme; F Ofosu; R Burrows; B Khambalia
Journal:  J Clin Invest       Date:  1992-01       Impact factor: 14.808

7.  Local abnormalities in coagulation and fibrinolytic pathways predispose to alveolar fibrin deposition in the adult respiratory distress syndrome.

Authors:  S Idell; K K James; E G Levin; B S Schwartz; N Manchanda; R J Maunder; T R Martin; J McLarty; D S Fair
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

Review 8.  Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditions.

Authors:  Matteo Cesari; Marco Pahor; Raffaele Antonelli Incalzi
Journal:  Cardiovasc Ther       Date:  2010-07-07       Impact factor: 3.023

9.  Deficiency of plasminogen activator inhibitor 2 in plasma of patients with hereditary angioedema with normal C1 inhibitor levels.

Authors:  Kusumam Joseph; Baby G Tholanikunnel; Bethany Wolf; Konrad Bork; Allen P Kaplan
Journal:  J Allergy Clin Immunol       Date:  2015-09-26       Impact factor: 10.793

10.  The pattern and magnitude of "in vivo thrombin generation" differ in women with preeclampsia and in those with SGA fetuses without preeclampsia.

Authors:  Offer Erez; Roberto Romero; Edi Vaisbuch; Juan Pedro Kusanovic; Shali Mazaki-Tovi; Tinnakorn Chaiworapongsa; Francesca Gotsch; Pooja Mittal; Samuel S Edwin; Chia-Ling Nhan-Chang; Nandor Gabor Than; Chong Jai Kim; Sun Kwon Kim; Lami Yeo; Moshe Mazor; Sonia S Hassan
Journal:  J Matern Fetal Neonatal Med       Date:  2017-05-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.